China Diagnostic Reagent Market Report, 2007-2009
  • Jul/2008
  • Hard Copy
  • USD $2,100
  • Pages:0
  • Single User License
    (PDF Unprintable)       
  • USD $2,200
  • Code:
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,300
  • Hard Copy + Single User License
  • USD $2,300
      

China's diagnostic reagent industry had lagged behind other countries for a long time. Since 1980s, China's reagent for clinical diagnosis has started entering the industrialization process, following the implementation of China's reform and open-up policy.

From the perspective of current situation in China, China's diagnostic reagent sector is still in its infancy. According to the statistics, China's current diagnostic reagent market size is around CNY3 billion to CNY4 billion, taking up around 1/14 of the global market. Though China's diagnostic reagent sector is just in its early stage, its high rate of profit return is a major factor to lure many investors into entering the market. Long-term competition in the sector has scaled largely down the number of companies. At present, the sector has a high degree of market concentration in key products. A group of powerful companies, such as Wantai Biological Pharmacy Enterprise Co., Ltd., Shanghai Kehua Bio-engineering Co., Ltd. and Kinghawk Pharmaceutical Co., Ltd., with good performance in R&D and production has developed rapidly, grabbing a considerable market share.

Clinical practice in the developed countries shows that diagnostic expenditure accounts for 20% to 30% of the total medical expenditure. But the ratio in China is less than 10%, indicating a huge market is to be exploited. It is forecast that China's vitro diagnostic reagent market will grow at a rate of around 20%. Opportunities are always accompanied by challenges. The development of China's diagnostic reagent sector in the next five years is still unknown, but it is well worth expecting.

Market value of diagnostic reagent increases faster than its output. Shifting from traditional microbiological test method to quick test method is the driver of the rapid growth of diagnostic reagent market. As for these new test methods, each of diagnostic reagents is of a higher price, but it is becoming more popular, as it is convenient and results come out faster than the traditional method. At present, the traditional test method with a total of 963 million doses takes up 79.8% of market share, and the quick test method with a total of 232 million doses, including convenient reagent, immunity reagent and molecule reagent, takes up 20.2% of market share.  

In 2008, the quick test method will grow exponentially, and the market share of the traditional test method is expected to drop to 69.4% in the full year. Each of reagents of the quick test method will have a considerable growth in the next five years and by then their annual output will be doubled on the basis of the current output. As the average price of the quick test reagent is higher than the traditional test reagent, so rises in prices will be more evident than increases in production.


Current Market Share of Traditional Test & Quick Test 
  诊断试剂.gif
Source: ResearchInChina

1. China's Diagnostic Reagent Market in Globalization Process
1.1 Impact of Globalization on China's Medicine Market
1.1.1 Pharmaceutical Industry Restructuring and International Division of Labor
1.1.2 Accelerated Globalization Process of Pharmaceutical Market 
1.1.3 International Status of China Pharmaceutical Industry
1.1.4 Forecast of China Status in Global Pharmaceutical Industry, 2009
1.2. Safety Factors of Economic Globalization, 2009
1.2.1 Developing Countries Participation in Economic Globalization
1.2.2 Strategy of Economic Globalization Launched by Developed Nations 
1.2.3 Impact of Globalization on Economic Safety of Developing Nations

2. Industrialization of Reagent for Clinical Diagnosis
2.1 Present Situation of China's Diagnostic Reagent Sector 
2.2 Prospect of China's Diagnostic Reagent Market
2.3 Scale of China's Diagnostic Reagent Market
2.4 China's Diagnostic Reagent Producers
2.5 Countermeasures of China's Diagnostic Reagent Sector
2.5.1 Development Features of China Diagnostic Reagent Market
2.5.2 Challenges and Opportunities
2.5.3 Development Trend of China Diagnostic Market

3. Clinical Diagnostic Reagent R&D
3.1 Development of Medical Inspection and Reagent for Clinical Diagnosis
3.2 Main Reagents for Clinical Diagnosis
3.2.1 Biochemical Reagent
3.2.2 Immunity Reagent
3.2.3 Molecular Diagnostic Reagent
3.2.4 Other Reagents Market

4. China's Diagnostic Reagent Market in 2008
4.1 Production Capacity of China's Diagnostic Reagent Sector
4.1.1 Producers
4.1.2 Market Size
4.1.3 Research and Development
4.2 Segmented Market
4.3 Market Capacity
4.4 Hospital Channels
4.4.1 Policy and Mode of Purchasing Medicine with Central Bidding
4.4.2 Hospital's Procurement and Management of Diagnostic Reagent

5. Segmented Market of Diagnostic Reagent 
5.1 Cardiovascular Diagnostic Reagent
5.1.1 Background and Reasons of Cardiovascular Disease
5.1.2 Relationship between Nutrition and Cardiovascular Disease
5.1.3 Genetic Revolution of Cardiovascular Diagnosis
5.1.4 Incidence of Cardiovascular Disease
5.1.5 New Stage of Cardiovascular Disease Prevention
5.1.6 New Mode of Cardiovascular Disease Prevention
5.1.7 Market of Test Reagent for the Detection of Cardiovascular Disease
5.2 Venereal Diagnostic Reagent
5.2.1 AIDS Incidence in China
5.2.2 Anti-AIDS Medicine Market
5.2.2.1 Overview of International Anti-AIDS Medicine Market
5.2.2.2 Clinical Application of Anti-AIDS Medicine in China
5.2.3 Incidence Rate of Venereal Disease and Morbidity Situation
5.2.4 Market Capacity of Venereal Disease Test Reagent
5.3 Hepatitis Diagnostic Reagent
5.3.1 Market of Test Reagent for the Detection of Hepatitis
5.4 Test Reagent for the Detection of Tumor
5.4.1 Tumor Markers and Clinical Application
5.4.1.1 Common Tumor Markers
5.4.1.2 Clinical Application of Various Tumor Markers
5.4.1.3 Incidence Rate of Tumor and Morbidity Situation
5.4.1.4 Future Direction of Cancer Diagnosis and Treatment
5.5 SARS Diagnostic Reagent R&D
5.6 HTLV Market and HTLV R&D
5.6.1 Introduction of HTLV 
5.6.1.2 Overseas Application of HTLV Test 
5.6.1.3 HTLV Test Reagent of WIT

6. China's Diagnostic Reagent Import and Export 
6.1 Import and Export
6.2 Global Diagnostic Reagent Export Structure
6.3 Regional Structure of Diagnostic Reagent Export in China
6.4 Trade Mode 

7. Diagnostic Reagent Producers
7.1 Overall Situation
7.2 Roche
7.2.1 Company Profile
7.2.2 Operation Status in 2008
7.2.3 Development Strategy
7.2.4 China in List of Nations for Roche Research and Development
7.2.5 Roche's Cancer Medicine Development
7.3 Abbott
7.3.1 Company Profile
7.3.2 Operation Status
7.4 Johnson and Johnson
7.4.1 Company Profile
7.4.2 Operation Status in 2008
7.4.3 Building A R&D Center in Shanghai
7.4.4 Building A Biopharmaceutical Plant in Ireland
7.5 GlaxoSmithKline
7.5.1 Company Profile
7.5.2 Operation Status in 2008
7.5.3 Development Strategy
7.6 Pfizer 
7.6.1 Company Profile
7.6.2 Company Profile

8. Domestic Key Enterprises, 2008-2009
8.1 FOSUN Pharmaceuticals (Group) Corporation 
8.1.1 Company Profile
8.1.2 Operation Status
8.1.3 Development Strategy
8.2 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. 
8.2.1 Company Profile
8.3 Shanghai Rongsheng Biotech Co., Ltd.
8.4 Shanghai Kehua Bio-engineering Co., Ltd.
8.4.1 Company Profile
8.4.2 Operation Status
8.5 Nanjing Jiancheng Bioengineering Institute
8.6 Livzon Syntpharm Co., Ltd. (Zhuhai FTZ)
8.6.1 Company Profile
8.6.2 Operation Status
8.7 Joint Ventures
8.7.1 Shanghai Fosun Long March Medical Science Co. Ltd. 
8.7.2 Huamei Biological Engineering Co. Ltd. 
8.8 Import Agents
8.8.1 Huasin Science Co. Ltd.
8.8.2 Beijing Bitab Biotech Co. Ltd.
8.8.3 Dalian Fanbang Chemical Technology Development Co. Ltd.
9. Development Trend of China's Diagnostic Reagent in 2009
9.1 Chinese Government Pays Much Attention To Developing Diagnostic Reagent
9.1.1 Regulate Management of Diagnostic Reagents
9.1.2 Approval and Registration of Diagnostic Reagents According to Law
9.1.3 Strengthening Supervision & Check of Diagnostic Reagents
9.1.4 Import & Export Policy
9.2 Prospect of China's Diagnostic Reagent Development in 2009
9.2.1 Profitability and Growth of Diagnostic Reagent Sector
9.2.1.1 Development Prospect of Diagnostic Reagent Sector 
9.2.1.2 Market Entry Barriers to Diagnostic Reagent Sector
9.2.1.3 Role of Gene Technology in Development of Diagnostic Reagent
9.2.2 Factors Affecting Development of Diagnostic Reagent Market
9.2.3 Development Trend of Diagnostic Reagents in 2009
9.2.4 Forecast of Output Value of Industrial Microbiological Test Reagents
9.2.5 Market Prospect of Vitro Diagnostic Reagents in 2009
9.2.6 Market Prospect of Diagnostic Reagent for Diabetes in 2009
9.2.7 Market Prospect of Anti-AIDS Medicine in 2009
9.2.8 Development Prospect of China Biopharmaceutical Market
9.2.9 Development Trend of Key Biopharmaceutical Technology in 2009

10. Strategies for Entering Diagnostic Reagent Market in 2009
10.1 Countermeasures about Products
10.2 Countermeasures about Market Competition
10.2.1 Capacity Expansion by Mergers and Restructuring 
10.2.2 Regional General Distribution System
10.2.3 Targeting the International GMP Pass
10.3 Market Entry Procedure and Investment in the Market
10.3.1 Product Quality Standards and Market Entry Examination
10.3.2 Investment in Diagnostic Reagents

11. Technical Environment - Global Biological Technology Market 
11.1 Market Prospect
11.1.1 Biological Technology Industry Development
11.1.2 Diagnostic Reagent Market
11.1.3 Forecast of Nucleic Acid Reagent Market
11.2 U.S.A. Market
11.2.1 Number and Size of Biological Technology Companies
11.2.2 R&D Funds in Biological Technology Market
11.2.3 Scale of Consumption

12. Economic Environment - China Biopharmaceutical Industry Development 
12.1 Operation of China's Biopharmaceutical Industry in 2007
12.1.1 Changes in Output Value of China Biopharmaceutical Industry in 2007
12.1.2 Changes in the Number of China Biopharmaceutical Companies in 2007 
12.1.3 Operation of China Biopharmaceutical Companies in 2007
12.1.4 Asset - Liability of China Biopharmaceutical Companies in 2007
12.1.5 Sales & Expenditure Cost of China Biopharmaceutical Firms in 2007
12.1.6 Profitability of China Biopharmaceutical Companies in 2007
12.1.7 Changes in Ownership Structure of Biopharmaceutical Industry in 2007 
12.1.8 Size Structure of China Biopharmaceutical Industry in 2007
Top 10 Diagnostic Reagent Producers in Terms of Sales and Market Share
Clinical Biological Reagent for Determination
Common EIA Reagent
Common Colloidal Gold Reagent
Common Chemiluminescence Reagent
Market Situation of Some Major Immunity Reagents
The Number of China's Diagnostic Reagent Companies
Ratio of Diagnostic Reagent Expense to the Total Diagnostic Expense
Market Share of Clinical Chemistry in Diagnostic Reagent Market
Market Share of Household Use of Diagnostic Reagent
Main Cardiovascular Diagnostic Reagents in China's Market 
Market Share of Foreign Diagnostic Reagent in China's HIV Market
Ratio of Wantai HIV Diagnostic Reagent Output to the National Total 
Hepatopathy Morbidity and Death Toll in China, Dec. 2007
Some Hepatitis Diagnostic Reagents in China
Clinical Application of Joint Detection of Common Tumor Markers
X-Ray Contrast Agent Import in Aug. 2007
X-Ray Contrast Agent Export in Aug. 2007
Import Value of Diagnostic Reagent, 2006-2007
Import & Export Value of Diagnostic Reagent in 2007
Comparison of Import Value of Diagnostic Reagent Between 2006 and 2007
Import & Export Volume of Diagnostic Reagent in 2007
Contrast of Export Value of Diagnostic Reagent Between 2006 and 2007
Contrast of Export Volume of Diagnostic Reagent Between 2006 and 2007
Contrast of Import Value of Diagnostic Reagent Between 2007 and 2008
Contrast of Import Volume of Diagnostic Reagent Between 2007 and 2008
Contrast of Export Value of Diagnostic Reagent Between 2007 and 2008
Contrast of Export Volume of Diagnostic Reagent Between 2007 and 2008
Global Monthly Diagnostic Reagent Export in Different Regions, 2007
China Top 10 Regions in Terms of Diagnostic Reagent Export Volume, 2007
China Top 10 Regions in Terms of Diagnostic Reagent Export Value, 2007
China Monthly Diagnostic Reagent Export in Different Regions, 2007
Import Volume & Value of Diagnostic Reagent Donated by Foreign Countries and International Organizations
Top 10 Pharmaceutical Giants, 2007
Forbes Top 10 Pharmaceutical Producers, 2007 (US$100 million)
Sales Revenue and Net Profit of Pharmaceutical Giants, 1Q2008
Global Pharmaceutical Market Growth, 2008
Sales Revenue Increase of Roche, Q1 2008
Rises in Prescription Drug Sales Revenue of Abbott, Q1 2008
Profitability of Johnson & Johnson, 2007-2008
Operating Ability of Johnson & Johnson, 2007-2008
Debt-paying Ability of Johnson & Johnson, 2007-2008
Capital Structure of Johnson & Johnson, 2007-2008
Development Ability of Johnson & Johnson, 2007-2008
Cash Flow of Johnson & Johnson, 2007-2008
Rankings of Pharmaceutical Producers among Fortune Global 500 Companies
Prescription Drug Sales Revenue of Pfizer, Q1 2008
Sales Revenue of Celecoxib and Celebrex in Pfizer, Q1 2008
GlaxoSmithKline Sales Revenue, Q1 2008
Anti-AIDS Medicine Sales Revenue of GlaxoSmithKline, Q1 2008
Subsidiaries Controlled by FOSUN
Companies Controlled by Subsidiaries of FOSUN
Profitability of FOSUN, 2007-2008
Operating Ability of FOSUN, 2007-2008
Debt-paying Ability of FOSUN, 2007-2008
Capital Structure of FOSUN, 2007-2008
Development Ability of FOSUN, 2007-2008
Cash Flow of FOSUN, 2007-2008
Main Products of Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Diagnostic Reagents of Wantai Biological Pharmacy Enterprise Co., Ltd.
Development Process of Shanghai Rongsheng Biotech Co., Ltd.
Development Process of Shanghai Kehua Bio-engineering Co., Ltd.
Subsidiaries of Shanghai Kehua Bio-engineering Co., Ltd.
R&D Process of Shanghai Kehua Bio-engineering Co., Ltd.
Revenue of Main Vitro Clinical Immunity Reagents of Shanghai Kehua 
Profitability of Shanghai Kehua Bio-engineering Co., Ltd., 2007-2008
Operating Ability of Shanghai Kehua Bio-engineering Co., Ltd., 2007-2008
Debt-paying Ability of Shanghai Kehua Bio-engineering Co., Ltd., 2007-2008
Capital Structure of Shanghai Kehua Bio-engineering Co., Ltd., 2007-2008
Development Ability of Shanghai Kehua Bio-engineering Co., Ltd., 2007-2008
Cash Flow of Shanghai Kehua Bio-engineering Co., Ltd., 2007-2008
Projects Financed by Fund Raising of Shanghai Kehua Bio-engineering Co.
Main Diagnostic Reagents of Nanjing Jiancheng Bioengineering Institute
Associated Companies of Livzon 
Profitability of Livzon, 2007-2008
Operating Ability of Livzon, 2007-2008
Debt-paying Ability of Livzon, 2007-2008
Capital Structure of Livzon, 2007-2008
Development Ability of Livzon, 2007-2008
Cash Flow of Livzon, 2007-2008
Global Top 10 Diagnostic Reagent Manufacturers
Market and R&D of American Biological Industry
Consumption Scale of American Diagnostic Reagent Market
Top 5 Nations in Terms of Market Share in Global Diagnostic Reagent Market Output Value of China's Biopharmaceutical Industry, 2007
The Number of China's Biopharmaceutical Companies, 2007
Operation Indices of China's Biopharmaceutical Industry, 2007
Balance Sheet of China's Biopharmaceutical Industry, 2007
Sales Revenue of China's Biopharmaceutical Industry, 2007
Production Expenses of China's Biopharmaceutical Industry, 2007
Profit and Tax of China's Biopharmaceutical Industry, 2007

China Interventional Cardiovascular Device Industry Report,2014-2017

The prevalence of cardiovascular disease in China impacted by accelerated aging of population and changes in consumption concept, dietary habit, way of working and other lifestyles has been growing ye...

China PTCA Balloon Market Investment Report, 2014-2016

PTCA balloon, as a indispensable medical device in percutaneous coronary intervention (PCI), serves not only as a delivery system for stent, but also as a device for pre-/post-stent dilatations. There...

China Orthopedic Instrument Industry Report, 2014-2017

Benefiting from accelerated aging population and rising proportion of reimbursement for medical expenses, the Chinese orthopedic instrument market demand has been effectively released, with its scale ...

China Hospital Development and Investment Report, 2014-2017

China hospital industry has been developing quickly in recent years, thanks to the market demand stimulus and steady progress in health care reform. The number of Chinese hospitals grew at a CAGR of 6...

China Diagnostic Reagent Industry Report, 2013-2016

With the accelerated aging of the Chinese population, the increase of personal health expenditure as well as the improved medical care facilities and government health care system, China diagnostic re...

China Hemodialysis Equipment Import and Export Report, 2013-2016

Hemodialysis equipment is the most widely used treatment apparatus in blood purification, primarily targeting patients with acute or chronic renal failure.The Chinese hemodialysis equipment market sho...

Global and China Hemodialysis Industry Report, 2013-2016

Hemodialysis, also known as artificial kidney, is a type of blood purification technology, primarily applicable to the treatment of patients with rental failure. In 2013, the global number of patient...

China Portable Medical Equipment Industry Report, 2013-2016

With the synergy of favorable policies, improvement in living standards and healthcare awareness raising, China’s portable medical device industry has shown rapid development in recent years, with mar...

China Medical Informatization Industry Report,2013-2016

Under the impetus of multiple favorable policies and market demand, China's medical informatization industry has entered a rapid development stage in recent years. As of the first half of 2013, manage...

China Aged Care Industry Report, 2013-2016

Currently, China has entered the accelerated aging period. China’s population aged 65 and above reached 131.61 million in 2013, accounting for 9.7% of total population; and the proportion will rise to...

China Pharmaceutical Equipment Industry Report, 2013-2016

After decades of development, China has become a major producer of pharmaceutical equipment in the world. Since 2010, affected by the new GMP certification and other factors, the revenue and total pro...

China Dental Industry Report, 2013-2016

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental appliances (equipments and consumables), dental medical services, etc. with...

China Medical Monitor Industry Report, 2013-2015

In 2007-2011, the Chinese medical monitor market size rose from RMB1.16 billion to RMB3.08 billion at a CAGR of 27.8%. In 2012, the figure reached RMB3.86 billion, a year-on-year increase of 25.3%, of...

China Interventional Cardiovascular Device Industry Report, 2013-2015

With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning Commission of the People’s Republi...

China Diagnostic Reagent Industry Report, 2013-2015

Driven by huge population base, intensified aging and many favorable policies, China diagnostic reagent industry has been developing rapidly. In 2008-2012, the diagnostic reagent market size presented...

China Orthopedic Instrument Industry Report, 2013-2015

Benefiting from aging of population, consumption upgrade and policy support, China's orthopedic instrument industry has seen rapid development over the years, with total market size rising from 3.28 b...

China Ophthalmic Hospital Industry Report, 2012-2015

With the growing types of eye diseases and non-basic medical needs, China’s ophthalmic hospital industry has seen rapid development. In 2011, the number of ophthalmic hospitals in China reached 288, w...

China Chinese Patent Medicine Industry Report, 2012-2015

In recent years, China’s Chinese patent medicine industry has been running in good condition, with the revenue increasing from RMB 142 billion in 2008 to RMB 360 billion in 2012 at a CAGR of 26.2%. Ov...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统